Ultragenyx and Kyowa Kirin Announce U.S. FDA Approves Label Update for Crysvita® (burosumab) for the Treatment of X-Linked Hypophosphatemia (XLH)

    NEXT STORY
    Acasti Pharma Announces Additional Phase 3 Milestones Reached, and Remains on Track to Report Topline Results for TRILOGY 1 in December 2019 and TRILOGY 2 in January 2020
    PREV STORY
    Cue Biopharma Initiates Patient Dosing in Phase 1 Study of CUE-101 for HPV16-driven Head and Neck Squamous Cell Carcinoma
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    TiGenix kondigt publicatie aan in Gastroenterology van week 52-gegevens van het fase III ADMIRE-CD onderzoek van Cx601

    PERSBERICHT TiGenix kondigt publicatie aan in Gastroenterology van week 52-gegevens van het fase III ...

    PM360 Staff
    PM360 Staff

    Global Infectious Diseases Partnering 2012-2018: Deal Trends, Players and Financials from Agreements by the World’s Leading Pharma and Biotech Companies

    Dublin, March 07, 2018 (GLOBE NEWSWIRE) -- The "Global Infectious Diseases Partnering 2012-2018: Deal ...

    author_avatar
    NASDAQ Market News

    Shire announces new hypoparathyroidism data at the 2018 European Congress of Endocrinology

    Shire announces new hypoparathyroidism data at the 2018 European Congress of Endocrinology New Burden ...

    author_avatar
    NASDAQ Market News